Prevention of hepatocellular carcinoma: Potential targets, experimental models, and clinical challenges

Yujin Hoshida, Bryan C. Fuchs, Kenneth K. Tanabe

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations


Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.

Original languageEnglish (US)
Pages (from-to)1129-1159
Number of pages31
JournalCurrent Cancer Drug Targets
Issue number9
StatePublished - 2012
Externally publishedYes


  • Animal model
  • Chemoprevention
  • Clinical trial
  • Hepatocellular carcinoma
  • Liver cirrhosis
  • Prevention

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research


Dive into the research topics of 'Prevention of hepatocellular carcinoma: Potential targets, experimental models, and clinical challenges'. Together they form a unique fingerprint.

Cite this